|
WO2020236808A1
|
|
Methods for preparing psma conjugates
|
|
JP2020117509A
|
|
Conjugates for treating diseases
|
|
CA3112806A1
|
|
Methods of treating cancer
|
|
WO2020061293A1
|
|
Shielding agents and their use
|
|
AU2019255692A1
|
|
Methods of treating cancer
|
|
TW202000229A
|
|
Sequencing method for CAR T cell therapy
|
|
WO2018160622A1
|
|
Compositions and methods for car t cell therapy
|
|
US2018125992A1
|
|
Drug delivery conjugates of tertiary amine containing drugs
|
|
CN110678204A
|
|
Folate conjugates for targeting tumor-associated macrophages
|
|
US2017348376A1
|
|
Tubulysin conjugate for use in treating cancer
|
|
WO2017205447A1
|
|
Methods of treating cancer with a psma ligand-tubulysin compound
|
|
US2020323991A1
|
|
Pbd conjugates for treating diseases
|
|
WO2017161144A1
|
|
Carbonic anhydrase ix inhibitor conjugates and uses thereof
|
|
WO2017066414A1
|
|
Drug delivery conjugates for use in combination therapy
|
|
WO2017031209A1
|
|
Tubulysin analogs and methods
|
|
EP3334466A1
|
|
Method of imaging with a chelating compound
|
|
US2018228909A1
|
|
CCK2R-drug conjugates
|
|
AU2016204030A1
|
|
Binding ligand linked drug delivery conjugates of tubulysins
|
|
WO2016179011A1
|
|
Antifolate conjugates for treating inflammation
|
|
WO2016168471A1
|
|
Dual disulfide drug conjugates
|
